Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 2
1979 2
1982 1
1983 1
1984 1
1985 2
1987 1
1988 1
1990 2
1991 2
1992 2
1993 1
1994 3
1995 1
1996 4
1997 2
1998 2
1999 2
2000 1
2001 4
2002 3
2003 4
2004 3
2005 2
2006 4
2007 3
2008 5
2009 4
2010 3
2011 6
2012 3
2013 4
2014 3
2015 5
2016 6
2017 4
2018 8
2019 3
2020 8
2021 5
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Armstrong PW, et al. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222134 Free article. Clinical Trial.
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, …
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection …
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients wit …
Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effec …
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221597 Free PMC article. Clinical Trial.
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
Remuzzi G, Macia M, Ruggenenti P. Remuzzi G, et al. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S90-7. doi: 10.1681/ASN.2005121324. J Am Soc Nephrol. 2006. PMID: 16565256 Review.
Prevention of the onset of microalbuminuria, therefore, could be considered as the primary means of preventing DN. The Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) was a prospective, randomized, double-blind, parallel-group study that was organized in …
Prevention of the onset of microalbuminuria, therefore, could be considered as the primary means of preventing DN. The Bergamo Nephrologic D …
4,4'-(Ethene-1,2-diyl)dipyridinium bis(2-hy-droxy-3-meth-oxy-benzoate).
Angevine DJ, Benedict JB. Angevine DJ, et al. IUCrdata. 2022 May 17;7(Pt 5):x220510. doi: 10.1107/S2414314622005107. eCollection 2022 May. IUCrdata. 2022. PMID: 36338936 Free PMC article.
In the title double proton-transfer salt, C(12)H(12)N(2) (2+).2C(8)H(7)O(4) (-), consisting of a 1:2 ratio of 4,4'-(ethene-1,2-diyl)dipyridinium cations (trans bipyridinium ethyl-ene) to 2-hy-droxy-3-meth-oxy-benzoate anions (o-vanillate), the complete cation is generated …
In the title double proton-transfer salt, C(12)H(12)N(2) (2+).2C(8)H(7)O(4) (-), consisting of a 1:2 ratio of 4,4'-(ethene-1,2-diyl)d …
Blastomycosis-Associated Hospitalizations, United States, 2010-2020.
Benedict K, Hennessee I, Gold JAW, Smith DJ, Williams S, Toda M. Benedict K, et al. J Fungi (Basel). 2023 Aug 22;9(9):867. doi: 10.3390/jof9090867. J Fungi (Basel). 2023. PMID: 37754975 Free PMC article.
Rates were consistently highest among persons 65 years old and males. In-hospital death occurred in 7.9% and approximately doubled from 3.9% in 2010 to 8.5% in 2020. Older age, chronic obstructive pulmonary disease, and malignancy were associated with mortality. ...
Rates were consistently highest among persons 65 years old and males. In-hospital death occurred in 7.9% and approximately doubled fr …
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
METHODS: In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), a multicenter, placebo-controlled, double-blind trial, statin-treated patients with controlled low-density lipoprotein cholesterol and mild to moderate hypertriglyceridemia …
METHODS: In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), a multicenter, placebo-controlled, do …
BENEDICT in the treatment of hypertension.
Logan A. Logan A. Curr Hypertens Rep. 2005 Apr;7(2):121-3. doi: 10.1007/s11906-005-0085-1. Curr Hypertens Rep. 2005. PMID: 15748536 Clinical Trial. No abstract available.
Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1499-1508. doi: 10.1056/NEJMoa1800722. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221596 Free PMC article. Clinical Trial.
Double burden of malnutrition and its association with infant and young child feeding practices among children under-five in Thailand.
Benedict L, Hong SA, Winichagoon P, Tejativaddhana P, Kasemsup V. Benedict L, et al. Public Health Nutr. 2021 Jul;24(10):3058-3065. doi: 10.1017/S1368980020003304. Epub 2020 Oct 15. Public Health Nutr. 2021. PMID: 33054885 Free PMC article.
In terms of IYCF indicators, despite no association with stunting and stunted-overweight children, current breast-feeding and inadequate meal frequency were associated with being wasting, while current breast-feeding and dietary diversity were inversely associated with being over …
In terms of IYCF indicators, despite no association with stunting and stunted-overweight children, current breast-feeding and inadequate mea …
116 results